AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
345.13B
Market cap345.13B
Price-Earnings ratio
82.32
Price-Earnings ratio82.32
Dividend yield
3.25%
Dividend yield3.25%
Average volume
8.39M
Average volume8.39M
High today
$195.78
High today$195.78
Low today
$191.01
Low today$191.01
Open price
$194.34
Open price$194.34
Volume
8.40M
Volume8.40M
52 Week high
$218.66
52 Week high$218.66
52 Week low
$153.58
52 Week low$153.58

ABBV News

Benzinga 16h
Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management named Netflix, Inc. NFLX as his final trade. On the earnings front, Netfli...

Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'
Simply Wall St 1d
AbbVie Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis

recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's...

AbbVie Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis
TipRanks 3d
AbbVie price target raised to $204 from $200 at BofA

BofA raised the firm’s price target on AbbVie (ABBV) to $204 from $200 and keeps a Neutral rating on the shares following what the firm calls a “decent quarter”...

Analyst ratings

62%

of 29 ratings
Buy
62.1%
Hold
34.5%
Sell
3.4%

More ABBV News

TipRanks 3d
AbbVie Stock Up 8% on the Week as Company Soars Past Q1 Expectations

AbbVie (ABBV) delivered impressive financial results for the first quarter of 2025. Investors responded enthusiastically, pushing AbbVie’s stock up 3.15% on the...

MarketWatch 5d
Drugmaker AbbVie says tax reform, not tariffs, would drive U.S. manufacturing - MarketWatch

...

Drugmaker AbbVie says tax reform, not tariffs, would drive U.S. manufacturing - MarketWatch
Sherwood News 5d
Botox sales slip as consumer sentiment wrinkles

As more economists raise their recession forecast and consumer sentiment wanes, wrinkles and thin lips might be the least of our worries. AbbVie, the largest B...

Botox sales slip as consumer sentiment wrinkles
Benzinga 6d
AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector

AbbVie Inc.'s ABBV stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast. The company reported an adjusted EP...

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
Sherwood News 6d
AbbVie rises as it beats Wall Street estimates, raises 2025 outlook

AbbVie rises as it beats Wall Street estimates, raises 2025 outlook AbbVie raised its profit outlook for 2025 after reporting sales and profit that beat Wall S...

AbbVie rises as it beats Wall Street estimates, raises 2025 outlook
TipRanks 6d
AbbVie’s Strong Financial Performance and Growth Potential Justifies Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on ABBV stock, giving a Buy rating on April 22. Matt Phipps has given his Buy rating due...

TipRanks 6d
ABBV Earnings: AbbVie Blows Past Q1 Estimates

Biopharmaceutical company AbbVie (ABBV) saw its stock jump on Friday following the release of its Q1 2025 earnings report. The company reported adjusted diluted...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.